Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 study to evaluate Dysport (abobotulinumtoxinA) for injection in the platysmal bands, the company reports
In addition, Galderma will be presenting new data at the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois
Specifically, this research will highlight Phase 3 results to support FDA submission for lip augmentation, as well as findings on measuring the flexibility of dermal fillers and ratings from the general public perceiving natural-looking results with XpresHAn technology fillers.Further, several studies evaluating the company's neurotoxin portfolio, including patient satisfaction and duration, will be presented during the meeting.
"Our comprehensive clinical research program is backed by a robust investment plan to support innovation over the next five years," says Xiaoming Lin, Global Head of Aesthetic Development at Galderma, in a news release. "Globally, Galderma currently has enrolled more than 6,000 patients across approximately 80 clinical trial sites with a total of 17 clinical studies underway."